AU782138B2 - Linezolid-crystal form II - Google Patents

Linezolid-crystal form II Download PDF

Info

Publication number
AU782138B2
AU782138B2 AU32755/01A AU3275501A AU782138B2 AU 782138 B2 AU782138 B2 AU 782138B2 AU 32755/01 A AU32755/01 A AU 32755/01A AU 3275501 A AU3275501 A AU 3275501A AU 782138 B2 AU782138 B2 AU 782138B2
Authority
AU
Australia
Prior art keywords
process according
solvent
fluoro
methyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU32755/01A
Other languages
English (en)
Other versions
AU3275501A (en
Inventor
Michael S. Bergren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22658183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU782138(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of AU3275501A publication Critical patent/AU3275501A/en
Application granted granted Critical
Publication of AU782138B2 publication Critical patent/AU782138B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU32755/01A 2000-02-02 2001-01-29 Linezolid-crystal form II Ceased AU782138B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17983700P 2000-02-02 2000-02-02
US60/179837 2000-02-02
PCT/US2001/000657 WO2001057035A1 (en) 2000-02-02 2001-01-29 Linezolid-crystal form ii

Publications (2)

Publication Number Publication Date
AU3275501A AU3275501A (en) 2001-08-14
AU782138B2 true AU782138B2 (en) 2005-07-07

Family

ID=22658183

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32755/01A Ceased AU782138B2 (en) 2000-02-02 2001-01-29 Linezolid-crystal form II

Country Status (30)

Country Link
EP (1) EP1255754B1 (enExample)
JP (1) JP5235256B2 (enExample)
KR (3) KR100781815B1 (enExample)
CN (1) CN1221547C (enExample)
AR (1) AR027261A1 (enExample)
AT (1) ATE297920T1 (enExample)
AU (1) AU782138B2 (enExample)
BR (1) BR0107667A (enExample)
CA (1) CA2395603C (enExample)
CO (1) CO5261555A1 (enExample)
CZ (1) CZ302292B6 (enExample)
DE (1) DE60111497T2 (enExample)
DK (1) DK1255754T3 (enExample)
EA (1) EA004434B1 (enExample)
EE (1) EE05197B1 (enExample)
ES (1) ES2242728T3 (enExample)
HU (1) HUP0301076A3 (enExample)
IL (1) IL151010A0 (enExample)
MX (1) MXPA02007471A (enExample)
MY (1) MY122829A (enExample)
NO (2) NO323459B1 (enExample)
NZ (1) NZ520541A (enExample)
PE (1) PE20011086A1 (enExample)
PL (1) PL356433A1 (enExample)
PT (1) PT1255754E (enExample)
SI (1) SI1255754T1 (enExample)
SK (1) SK287025B6 (enExample)
TW (1) TWI297687B (enExample)
WO (1) WO2001057035A1 (enExample)
ZA (1) ZA200205162B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100490643B1 (ko) * 2002-10-29 2005-05-19 한국과학기술연구원 새로운 메틸리덴 피페리딘일 옥사졸리딘온 유도체 및이들의 제조방법
ES2803516T3 (es) 2003-10-16 2021-01-27 Symed Labs Ltd Una forma cristalina de linezolid
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
EP1658275A1 (en) * 2004-06-29 2006-05-24 Teva Pharmaceutical Industries Ltd Crystalline form iv of linezolid
EP1745028A2 (en) * 2004-06-29 2007-01-24 Teva Pharmaceutical Industries Ltd Solid forms of linezolid and processes for preparation thereof
WO2006091731A2 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
KR20070062504A (ko) * 2005-06-22 2007-06-15 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 말레이트의 다형태
DK1749517T3 (da) * 2005-07-20 2008-11-03 Teva Pharma Stabil farmaceutiske sammensætning af linezolid form IV
WO2007102082A1 (en) * 2006-03-09 2007-09-13 Glenmark Pharmaceuticals Limited High oxazolidinone content solid dosage forms
WO2008127300A2 (en) * 2006-10-23 2008-10-23 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
WO2011050826A1 (en) 2009-10-28 2011-05-05 Synthon B.V. Process for making crystalline form a of linezolid
CN103025730A (zh) 2010-04-30 2013-04-03 印第安纳大学研究及科技有限公司 制备利奈唑胺的方法
EP2690100A1 (en) 2010-08-11 2014-01-29 Synhton B.V. Process for making linezolid
WO2012019632A1 (en) 2010-08-11 2012-02-16 Synthon B.V. Process for making linezolid
EP2593440A1 (en) * 2011-02-24 2013-05-22 Lee Pharma Limited Anhydrous linezolid crystalline form-ii
WO2012119653A1 (en) 2011-03-09 2012-09-13 Synthon Bv Process for making crystalline form a of linezolid
CN102731341A (zh) * 2011-04-13 2012-10-17 上海医药工业研究院 用于制备利奈唑胺的中间体及其制备方法
CN105461648B (zh) * 2011-05-03 2018-01-12 江苏豪森药业集团有限公司 利奈唑胺的晶型及其制备方法
CN102399200B (zh) * 2011-12-14 2013-12-04 浙江新东港药业股份有限公司 一种利用悬浮结晶法制备利奈唑胺晶型ⅰ的方法
WO2013111048A1 (en) 2012-01-24 2013-08-01 Jubilant Life Sciences Limited Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent
WO2013120496A1 (en) 2012-02-14 2013-08-22 Pharmathen S.A. Process for the preparation of linezolid in crystalline form and salts thereof
CN102643245A (zh) * 2012-04-10 2012-08-22 杭州华东医药集团生物工程研究所有限公司 一种利奈唑胺晶型及其制备方法
ES2603252T3 (es) 2012-11-09 2017-02-24 Synthon Bv Proceso para preparar linezolid
US20190343761A1 (en) 2016-11-16 2019-11-14 Persica Pharmaceuticals Ltd. Antibiotic formulations for lower back pain
EP3709970B1 (en) * 2017-11-16 2025-05-14 Persica Pharmaceuticals Ltd. Linezolid formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5837870A (en) * 1996-04-11 1998-11-17 Pharmacia & Upjohn Company Process to prepare oxazolidinones
WO1999024393A1 (en) * 1997-11-07 1999-05-20 Pharmacia & Upjohn Company Process to produce oxazolidinones

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
MY115155A (en) * 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5837870A (en) * 1996-04-11 1998-11-17 Pharmacia & Upjohn Company Process to prepare oxazolidinones
WO1999024393A1 (en) * 1997-11-07 1999-05-20 Pharmacia & Upjohn Company Process to produce oxazolidinones

Also Published As

Publication number Publication date
SI1255754T1 (sl) 2005-12-31
CN1221547C (zh) 2005-10-05
NO323459B1 (no) 2007-05-14
WO2001057035A1 (en) 2001-08-09
SK9942002A3 (en) 2002-11-06
CZ302292B6 (cs) 2011-02-09
CO5261555A1 (es) 2003-03-31
PT1255754E (pt) 2005-11-30
PL356433A1 (en) 2004-06-28
ZA200205162B (en) 2003-09-29
CA2395603C (en) 2010-03-23
ES2242728T3 (es) 2005-11-16
DK1255754T3 (da) 2005-08-22
MXPA02007471A (es) 2002-12-13
SK287025B6 (sk) 2009-10-07
NO20023654D0 (no) 2002-08-01
EE200200420A (et) 2003-12-15
MY122829A (en) 2006-05-31
CN1394207A (zh) 2003-01-29
KR100781815B1 (ko) 2007-12-03
JP5235256B2 (ja) 2013-07-10
KR20020072300A (ko) 2002-09-14
JP2003522175A (ja) 2003-07-22
NZ520541A (en) 2004-02-27
EP1255754B1 (en) 2005-06-15
DE60111497T2 (de) 2006-05-18
KR20070087178A (ko) 2007-08-27
EE05197B1 (et) 2009-08-17
ATE297920T1 (de) 2005-07-15
NO20023654L (no) 2002-08-01
HK1051196A1 (en) 2003-07-25
KR100864745B1 (ko) 2008-10-22
PE20011086A1 (es) 2001-10-04
TWI297687B (en) 2008-06-11
KR20080044358A (ko) 2008-05-20
AR027261A1 (es) 2003-03-19
IL151010A0 (en) 2003-02-12
AU3275501A (en) 2001-08-14
NO20065836L (no) 2002-08-01
EA004434B1 (ru) 2004-04-29
HUP0301076A3 (en) 2004-06-28
CA2395603A1 (en) 2001-08-09
EA200200819A1 (ru) 2003-02-27
DE60111497D1 (de) 2005-07-21
HUP0301076A2 (hu) 2003-08-28
CZ20022635A3 (cs) 2002-10-16
EP1255754A1 (en) 2002-11-13
BR0107667A (pt) 2002-10-08

Similar Documents

Publication Publication Date Title
US6444813B2 (en) Linezolid-crystal form II
CA2395603C (en) Linezolid-crystal form ii
ES2803516T3 (es) Una forma cristalina de linezolid
EP2825525A1 (en) New polymorphic form of a long-acting beta-2 adrenoceptor agonist
HK1051196B (en) Linezolid-crystal form ii
JP7704835B2 (ja) ビランテロールトリフェナテートの精製方法
KR0173861B1 (ko) N-치환된 티오카바모일기를 포함하는 신규한 카바메이트 화합물과 이의 제조방법
WO2005122698A2 (en) Novel stable polymorphic forms of tiagabine hydrochloride